Simulations Plus (NASDAQ:SLP) Upgraded at StockNews.com

StockNews.com upgraded shares of Simulations Plus (NASDAQ:SLP) from a sell rating to a hold rating in a research report report published on Monday morning.

Other research analysts have also recently issued research reports about the company. KeyCorp upped their price target on Simulations Plus from $32.00 to $40.00 and gave the company an “overweight” rating in a research report on Wednesday, April 16th. William Blair restated an “outperform” rating on shares of Simulations Plus in a research note on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $50.00.

Simulations Plus Stock Performance

SLP opened at $34.35 on Monday. Simulations Plus has a fifty-two week low of $23.01 and a fifty-two week high of $51.22. The firm has a 50-day moving average of $28.53 and a 200 day moving average of $30.35. The firm has a market cap of $690.81 million, a P/E ratio of 85.88 and a beta of 1.13.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.06. The firm had revenue of $22.43 million for the quarter, compared to analysts’ expectations of $21.93 million. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The company’s quarterly revenue was up 22.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.20 earnings per share. Equities research analysts predict that Simulations Plus will post 1.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Walter S. Woltosz sold 20,000 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $33.91, for a total transaction of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares of the company’s stock, valued at approximately $115,381,623.44. This represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 19.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of SLP. Janus Henderson Group PLC grew its position in shares of Simulations Plus by 7,753.3% in the 4th quarter. Janus Henderson Group PLC now owns 542,899 shares of the technology company’s stock worth $15,141,000 after buying an additional 535,986 shares during the last quarter. Conestoga Capital Advisors LLC raised its holdings in shares of Simulations Plus by 17.2% during the first quarter. Conestoga Capital Advisors LLC now owns 2,609,388 shares of the technology company’s stock valued at $63,982,000 after acquiring an additional 383,126 shares in the last quarter. Royce & Associates LP lifted its stake in Simulations Plus by 56.6% in the fourth quarter. Royce & Associates LP now owns 371,797 shares of the technology company’s stock worth $10,369,000 after acquiring an additional 134,381 shares during the period. Nicholas Company Inc. bought a new stake in Simulations Plus in the fourth quarter valued at $3,418,000. Finally, Kennedy Capital Management LLC increased its position in Simulations Plus by 59.4% during the 4th quarter. Kennedy Capital Management LLC now owns 289,286 shares of the technology company’s stock valued at $8,068,000 after purchasing an additional 107,766 shares during the period. Hedge funds and other institutional investors own 78.08% of the company’s stock.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.